 "hydroxychloroquine, hcq, drugs, coronavirus, pharma")
An international trial using hydroxychloroquine to treat Covid-19 patients will be restarted after questions arose about a study linking the antimalarial drug to increased death and heart risks.
The World Health Organization said Wednesday that it will resume recruiting patients for the hydroxychloroquine arm of a global trial called Solidarity. The agency had paused the branch of the experiment, which compares the impact of a number of treatment regimens, after the drug was linked to heart risks in research published in the Lancet, a medical journal.
The move adds to the confusion that’s erupted since more than 200 scientists began
